The agency shared information from reports by users of compounded semaglutide and tirzepatide who have experienced health ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach?

Next-generation weight-loss pills could hit the market in the coming months, with new data raising a key question: Will ...

SGLT-2 inhibitor and GLP-1 receptor agonist drugs should be used in all or almost all adults with type 2 diabetes at higher ...

Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...

The Hunting Wives' actress Chrissy Metz gets candid in a new cover story for PEOPLE on her thoughts about using weight loss ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

In a clinical trial, the company's weight loss pill resulted in a nearly 12% weight loss at 72 weeks for participants who took the highest dose of the medication. On average, participants lost 7.8% to ...

New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an increased risk of rare eye conditions.

GLP-1 medications have an impressive history of weight loss, but there are options to consider. For example, one study on the oral medication Qsymia found people lost up to 11% of their body ...